ArticleFrontiers in oncology2026
The clinical significance and prognostic implication of autophagy-related gene 13 in human gastric cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Gastric cancer remains a leading cause of cancer-related death worldwide, underscoring the need for novel prognostic biomarkers to guide personalized therapy. Previous studies have identified that the autophagy-related gene 13 (ATG13) plays an essential role in cell biological processes, while its clinical significance and prognostic values in gastric cancer remain unclear. Methods: Bioinformatic analyses were conducted to assess the transcription levels and genomic alterations of the ATG13 gene in gastric cancer. Immunohistochemistry was also utilized to evaluate the association between ZHX3 protein expression and clinicopathologic variables as well as patient survival. In addition, cell proliferation, colony formation and invasion assays were performed to examine the impacts of silencing ATG13 expression on gastric cancer cell growth and metastasis. Results: ATG13 expression was significantly elevated in gastric cancer tissues compared to noncancerous tissues, which was strongly associated with large tumor size and poor outcomes in patients with gastric cancer. Multivariate analysis indicated that ATG13 expression was an independent prognostic indicator for patient survival. Silencing ATG13 expression functionally inhibited growth and metastasis of gastric cancer cells. Conclusion: The above findings suggest that dysregulation of ATG13 expression is involved in gastric cancer progression and may serve as a candidate survival biomarker for this malignancy, which warrant further validation by further
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.